How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with LARVOL. ? #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch #Cancer #CancerData #OncologyData | Bruno Larvol
LARVOL
IT 服务与咨询
San Francisco，California 13,157 位关注者
Leveraging AI to turn clinical trial data and market intelligence into actionable insights to accelerate innovation.
关于我们
AI-powered data and market intelligence solutions - We leverage AI to transform clinical trial data and market intelligence into actionable insights to accelerate pharma innovation, competitive strategy, and patient outcomes. Our solutions include KOL monitoring, real-time high-impact news, intuitive cancer biomarker database and comprehensive conference planners. To keep you at the forefront of clinical and industry developments, LARVOL curates pharmaceutical and biotech competitive intelligence using a proven combination of broad therapeutic-area expertise and technological innovation. Our team of MDs and PhDs collates data from over 25,000 sources and distills the most relevant findings into concise reports that provide real-time insights and time-saving analysis. Our global team is comprised of professionals with expertise in all major therapeutic areas, with a special focus on oncology, inflammation, cardiovascular, and CNS. We are a valued partner to numerous Fortune 500 companies as well as small and mid-size pharma and biotech enterprises.
- 网站
-
https://www.larvol.com
LARVOL的外部链接
- 所属行业
- IT 服务与咨询
- 规模
- 51-200 人
- 总部
- San Francisco，California
- 类型
- 私人持股
- 创立
- 2004
- 领域
- Financial analyst monitoring、Scientific Conferences、life sciences、medical conferences和healthcare
产品
![点击此处查看OMNI]()
OMNI
Business Intelligence (BI) Software
Stay up-to-date with all aspects of your KOL activity. OMNI makes it easy with complete coverage of both on and offline news delivered in real-time to your inbox and our user-friendly online platform.
地点
-
主要
获取路线
548 Mission St
Suite 44120
US，California，San Francisco，94105
LARVOL员工
动态
-
Dr. Guru Sonpavde, MD joins Dr. Mark Gramling to discuss the latest developments in GU oncology from ASCO GU. They focus on the results of the TALAPRO trial, exploring its impact on metastatic castration-resistant prostate cancer (mCRPC) and whether new data could change clinical practices. The discussion also covers the NIAGARA study, showing promising results for perioperative durvalumab in urothelial carcinoma. #LARVOL #GU #ONCOLOGY
GU Oncology Insights | LARVOL Onco Data Podcast with Dr. Guru Sonpavde
www.dhirubhai.net
-
The FDA has issued a second rejection for the approval of rivoceranib plus camrelizumab as a first-line treatment for unresectable HCC.? ? Here is the updated tracker of upcoming PDUFA dates and latest FDA approvals in oncology! ? Access real-time market intelligence and latest oncology insights with LARVOL PULSE.? ? Check out the past FDA approvals: https://lnkd.in/gKW5PHXd ? #LARVOL #CancerResearch #PDUFA #Oncology #CancerData #ClinicalTrials #OncologyInsight Engage with the top voices on X discussing the latest PDUFA updates: Prof. Dr. Arndt Vogel | Stephen Liu | Cathy Eng | Neeraj Agarwal, MD, FASCO | Petros Grivas | Melvin L.K. Chua | Yelena Janjigian | Ane Gerda Zahl Eriksson | Amol Akhade
-
Final overall survival (OS) from the phase III MARIPOSA study: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC. #LARVOL #CancerResearch #LungCancer #EGFR #Oncology #NSCLC #ELCC25 #MARIPOSA #CancerData #ClinicalTrials | Amol Akhade | LARVOL |?ESMO - European Society for Medical Oncology
-
March is National Colorectal Cancer Awareness Month, dedicated to raising awareness about the importance of screening, prevention, and early detection of colon and rectal cancer. Here are the Key CRC Regimens from the American Society of Clinical Oncology (ASCO)-GI 2025. Connect with some of the top voices on X in the field of Colorectal Cancer: Pashtoon Kasi | Cathy Eng | Myriam Chalabi | Wafik S. El-Deiry, MD, PhD, FACP | Aparna Parikh | Ray DuBois | Marwan Fakih | Ibrahim Halil Sahin | Prof. Dr. Arndt Vogel | Tanios Bekaii-Saab | Amol Akhade | LARVOL #LARVOL #ColorectalCancer #RectalCancer #CRC #CancerResearch #Oncology #CancerData #ClinicalTrials #OncologyInsight #GI25
-
-
Watch the 25th episode of LARVOL CLIN: Building in Public, where Kalpana Devi joins Bruno Larvol to explore the MARIPOSA trial, its key data, and oncologists' reactions—all on the LARVOL CLIN platform. Watch Now: https://lnkd.in/gGt42KUK #LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #LARVOLCLIN #MARIPOSA
-
-
ELCC 2025: The abstracts and late-breaking presentations are here. Follow us for the latest updates and insights. #LARVOL #ELCC25 #LungCancer #Oncology #OncologyInsights #CancerData #ClinicalTrials | LARVOL | ESMO - European Society for Medical Oncology
-
-
The ELCC 2025 abstracts have been released! Follow us for more updates. #LARVOL #ELCC25?#LungCancer #Oncology #OncologyInsights #CancerData #ClinicalTrials | LARVOL | ESMO - European Society for Medical Oncology
-
-
LARVOL转发了
How accurately can AI models correctly identify the presence of FDA black box warnings? Here are the latest benchmark results. #LARVOL #CancerResearch #Oncology #CancerData #ClinicalTrials #ChatGPT #Grok #Gemini #Qwen #Llama #MistralAI #Claude | Bruno Larvol | LARVOL | Amol Akhade | Daniel J. | OpenAI | Mistral AI